DEPDC5

Across TCGA pan-cancer cohorts, DEPDC5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DEPDC5 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DEPDC5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEPDC5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where DEPDC5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.542	0.955	.020	9	view →
CCRCC	DFS	Median	II,III,IV	0.935	0.807	.028	2	view →
GBM	DFS	Median	All	0.259	0.480	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DEPDC5–PDAC (DFS)

Open the PDAC breakdown →